Patient Preference for Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam or Topical Suspension vs. Latest Topical Treatment in the PSO-INSIGHTFUL Study. J of Skin [Internet]. 2017 Oct. 27 [cited 2025 Apr. 19];1(3.1):s26. Available from: https://skin.dermsquared.com/skin/article/view/172